Guardant360 Response™

  • Assess changes in

    ctDNA to help clarify

    equivocal scans.2

  • Results in under

    2 weeks.*

  • Covered by Medicare

    for all solid tumors.†

Predict treatment response before standard imaging.1


Assess response to therapy 4-10
weeks after treatment initiation.3

Molecular responders had significantly longer
PFS vs non-responders.1

On-treatment ctDNA dynamics are:

  • an early predictor of long-term
    benefits of therapy1

  • complementary to standard imaging1

PFS by Cancer Type

Graph comparing progression-free survival for NSCLC, Breast cancer, gastric cancer, and bladder cancer

Order a kit

References: 1. Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842-1853. doi:10.1158/2159-8290.CD-20-0047 2. Thompson JC, Carpenter EL, Silva BA, et al. Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy. JCO Precis Oncol. 2021;5:510-524. doi:10.1200/PO.20.00321 3. Guardant360® Response: Guide to Ordering Guardant360 Response. Guardant Health, Inc. Redwood City, CA. 4. Raja R, Kuziora M, Brohawn PZ, et al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin Cancer Res. 2018;24(24):6212-6222. doi:10.1158/1078-0432.CCR-18-0386 5. Modi S, Andre F, Krop IE, et al. Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis. ASCO Annual Meeting. 2020. doi:10.1200/JCO.2020.38.15_suppl.1036 6. Maron SB, Chatila WK, Millang BM, et al. Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): plasma and tumor-based biomarker analysis. J Clin Oncol. 2020;38(suppl 15):4559. doi:10.1200/JCO.2020.38.15_suppl.4559